Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Inv. presentation
Cert. of designation
Appointed director

Bionik Laboratories Corp. (BNKL) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/30/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
06/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SUBSCRIPTION AGREEMENT",
"BIONIK LABORATORIES CORP. CONVERTIBLE PROMISSORY NOTE",
"Signature on the Following Page 5 In Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove written. Bionik Laboratories Corp. By: Name: Title: HOLDER: Name: SIGNATURE PAGE TO PROMISSORY NOTE"
06/16/2023 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
05/31/2023 SD Form SD - Specialized disclosure report:
05/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories Reports a Significant Increase in Patient Volume at its Acquired Rehabilitation Center in Florida"
05/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories Enters into Distribution Agreement with Pro-Med Technology for the Sale of InMotion® Robotic Devices in Hong Kong"
04/26/2023 8-K Quarterly results
02/23/2023 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "SUBSCRIPTION AGREEMENT",
"BIONIK LABORATORIES CORP. CONVERTIBLE PROMISSORY NOTE"
02/08/2023 8-K Quarterly results
02/08/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/20/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
12/20/2022 8-K Quarterly results
12/07/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/07/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/17/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
11/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories to Present at the Q4 Virtual Investor Summit"
11/04/2022 8-K/A Quarterly results
10/25/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
10/13/2022 4 Russo Richard Paul Jr (CEO and President) has filed a Form 4 on Bionik Laboratories Corp.
Txns: Granted 60,000 options to buy @ $0.302, valued at $18.1k
10/13/2022 8-K Amended existing or entered into new employment agreement with an officer
Docs: "SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to the Employment Agreement dated as of the Start Date , as amended pursuant to that First Amendment to Employment Agreement dated October 15, 2021 , by and between Bionik Laboratories Corp., a Delaware corporation, and Richard Russo, is made as of the 6th day of October, 2022 , by and between the Company and the Employee . RECITALS WHEREAS, the Company and the Employee are parties to the Agreement; and WHEREAS, the Company and the Employee desire to amend the Agreement as more particularly set forth herein; and WHEREAS, Section 6.6 of the Agreement provides, in part, that no amendment to the Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties thereto. NOW, THEREFORE, in cons...",
"EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, is made as of the Start Date , by and between BIONIK LABORATORIES CORP., a Delaware corporation , and Dan Gonsalves . RECITALS WHEREAS, the Company, directly or through its subsidiaries, is engaged in the business of medical device research, development and production; and WHEREAS, the Company and the Employee have agreed to enter into an employment relationship upon the terms and subject to the conditions hereinafter set forth. NOW THEREFORE, in consideration of the mutual covenants and promises herein contained and other good and valuable consideration, the parties agree as follows: ARTICLE 1- EMPLOYMENT AND DUTIES 1.1 Appointment . Subject to the terms and conditions of this Agreement, the Company hereby agrees to employ the employee, and ...",
"Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer"
09/08/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories Acquires Florida Rehabilitation Center; First in Strategic National Rollout"
09/07/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "BALANCE DUE AT CLOSING",
"BIONIK LABORATORIES CORP. SECURED CONVERTIBLE PROMISSORY NOTE",
"COLLATERAL PLEDGE AGREEMENT"
09/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BIONIK Laboratories to Present at National Investment Banking Association Conference"
08/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/16/2022 8-K Quarterly results
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Gaston-Dreyfus Remi (10% Owner) has filed a Form 4 on Bionik Laboratories Corp.
Txns: Converted 77,887 shares @ $9.5, valued at $739.9k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy